Colorado Springs, Co. – Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the Society of NeuroInterventional Surgery (SNIS) 14th Annual Meeting. CERENOVUS, a name derived from the Latin words for ‘new’ and ‘brain’, will focus on delivering innovative therapies for hemorrhagic and ischemic stroke patients.
On June 13-15, the 20th “Live International Neuroradiology and Neurosurgery Course” took place. Specialists of neuroradiology met at the Carrousel du Louvre in Paris, to discuss live cases which were presented from all over the world. phenox has sponsored the LINNC for years. This year was the first time phenox was a silver sponsor of the meeting and was present with a booth, a training area as well as its own symposium.
Kalamazoo, Michigan, USA – March 07, 2017 – Stryker announced an early end to patient enrollment in the DAWN Trial, a clinical study designed to compare mechanical thrombectomy with the Trevo® Retriever plus medical therapy against medical therapy alone when initiated within six to 24 hours after time last known well. The independent Data Safety Monitoring Board (DSMB) recommended stopping study enrollment based on a pre-planned interim review of data from the first 200 patients, which concluded that multiple pre-specified stopping criteria were met. A final analysis of the data will be conducted upon completion of the remaining patient follow-up.